IP Library Granted Patent US 9,192,507
Granted Patent B2
US 9,192,507 · App. 13/704,220 · Granted Nov 24, 2015

Tissue crosslinking for treatment of snoring and obstructive sleep apnea

Inventors: Thomas P. Hedman (Lexington, KY); Pawel Slusarewicz (Lexington, KY)
Assignee: Orthopeutics, L.P.
A61F5/56A61F5/566A61K31/11A61K31/352A61M2202/0007A61M2210/0618
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,192,507
App. No.
13/704,220
Granted
Nov 24, 2015
Kind
B2
Abstract

A method of treating snoring and/or OSA in a subject in need of such treatment. The method includes crosslinking proteins of the subject's soft palate tissue or pharynx tissue. The crosslinking can occur by contacting the soft palate or pharynx tissue with a crosslinking reagent. In addition, the crosslinking can occur without heating, contracting or denaturing of the tissue, or any combination thereof.

Claims (25)

1. A method of treating snoring and/or obstructive sleep apnea (OSA) in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue,

wherein the crosslinking reagent is delivered to the soft palate or pharynx tissue via a patch, a strip-type delivery device, or any combination thereof, and wherein the patch or delivery device is non-biodegradable and porous, and the crosslinking reagent is embedded within the pores.

2. A method of treating snoring and/or OSA in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue,

wherein the crosslinking reagent is delivered to the soft palate or pharynx tissue via a patch, and wherein the patch is non-biodegradable and the crosslinking reagent is adhered to one side of the patch as part of a semi-solid formulation.

3. A method of treating snoring and/or OSA in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue,

wherein the crosslinking reagent is delivered to the soft palate or pharynx tissue via a patch, a strip-type delivery device, or any combination thereof, and wherein the patch or delivery device is biodegradable and comprises a basic salt.

4. The method of claim 3 , wherein the salt is calcium carbonate, calcium hydroxyapatite, sodium bicarbonate, 2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).

5. A method of treating snoring and/or OSA in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue,

wherein the crosslinking reagent is delivered to the soft palate or pharynx tissue via a patch, a strip-type delivery device, or any combination thereof, and wherein the patch or delivery device is coated with one or more layers of crosslinking reagent-containing biodegradable polymer.

6. The method of claim 5 , wherein each layer comprises a basic salt.

7. The method of claim 6 , wherein the salt is calcium carbonate, calcium hydroxyapatite, sodium bicarbonate, 2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) or 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES).

8. The method of claim 5 , wherein the patch or delivery device is coated with multiple layers of crosslinking reagent-containing biodegradable polymer, and the crosslinking reagent varies from layer to layer.

9. A method of treating snoring and/or OSA in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue,

wherein the crosslinking reagent is delivered to the soft palate or pharynx tissue via a patch, and the patch is affixed to the tissue with a bio-compatible adhesive, and wherein the adhesive is poly(glycerol-co-sebacate acrylate), an oleic methyl ester or an alkyl ester cyanoacrylate.

10. A method of treating snoring and/or OSA in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue, wherein the crosslinking reagent is genipin and wherein said genipin is at a concentration of about 10 to 60 mM in about 50 mM 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) buffer at about pH 9 with about 50 mM phosphate ions.

11. A method of treating snoring and/or OSA in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue, wherein the crosslinking reagent is methylglyoxal and wherein said methylglyoxal is at a concentration of about 10-60 mM in about 50 mM 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) buffer at about pH 9 with about 50 mM phosphate ions.

12. The method of claim 1 , comprising further delivering the crosslinking reagent via injection, spraying, or a combination thereof.

13. The method of claim 2 , comprising further delivering the crosslinking reagent via injection, spraying, a strip-type delivery device, or a combination thereof.

14. The method of claim 3 , comprising further delivering the crosslinking reagent via injection, spraying, or a combination thereof.

15. The method of claim 5 , comprising further delivering the crosslinking reagent via injection, spraying, or a combination thereof.

16. The method of claim 9 , comprising further delivering the crosslinking reagent via injection, spraying, a strip-type delivery device, or a combination thereof.

17. The method of claim 10 , wherein the crosslinking reagent further comprises one or more of methylglyoxal, L-threose, D-threose, proanthocyanidin, EDC, or glutaraldehyde.

18. The method of claim 11 , wherein the crosslinking reagent further comprises one or more of genipin, L-threose, D-threose, proanthocyanidin, EDC, or glutaraldehyde.

19. A method of treating snoring and/or OSA in a subject in need of such treatment, comprising changing the mechanical properties of the subject's tissues by crosslinking tissue proteins within the subject's soft palate tissue or pharynx tissue, the crosslinking comprising contacting the soft palate or pharynx tissue with a crosslinking reagent which subsequently diffuses into the tissue, wherein the crosslinking reagent is genipin and wherein said genipin is at a concentration of about 40 to 60 mM in about 50 mM 4-(2-Hydroxyethyl)-1-piperazinepropanesulfonic acid (EPPS) buffer at about pH 8 with about 25-100 mM phosphate ions.

20. The method of claim 19 , wherein the phosphate ion concentration is about 50 mM.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: ORTHOPEUTICS, LP
To: ORTHOPEUTICS GROUP, LLC
Reel/Frame 060094/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: ORTHOPEUTICS GROUP, LLC
To: SPINAL SIMPLICITY, LLC
Reel/Frame 060094/0942 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2012
From: HEDMAN, THOMAS P.; SLUSAREWICZ, PAWEL
To: ORTHOPEUTICS, L.P.
Reel/Frame 029502/0673 →
Continuity (4)
Continuation In Part 10230671 · Aug 29, 2002
Provisional Application 61359202 · Jun 28, 2010
Provisional Application 60316287 · Aug 31, 2001
Related Publication 20130087155A1 · Apr 11, 2013